medigraphic.com

2002, Number S1

<< Back Next >>

Arch Cardiol Mex 2002; 72 (S1)

Gen therapy in cardiology

Jay D

Language: Spanish
References: 10
Page: 91-94
PDF size: 51.27 Kb.


ABSTRACT

The modification of genetic material of living cells for therapeutic purposes have been regarded by many as an unrealized promise. However, recent successful achievements in the field have contributed to vanish this perception and have reopened the possibility to use gene therapy as a medical intervention in humans. In the case of cardiovascular diseases, and despite its high prevalence, the number of approved human gene therapy protocols has remained low. This may be due, at least in part, to the availability of effective alternative therapies for some of the most common vasculopathies. However, recent advances in the understanding of the genetic and molecular bases of the cardiovascular system have opened the possibility to introduce gene therapy in the management of a great variety of cardiovascular disorders. The purpose of this communication is to briefly summarize the progress in this area.


REFERENCES

  1. Trisha G: After a Setback, Gene Therapy Progresses. Science 2001; 291: 1692-1697.

  2. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344.

  3. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 627-629.

  4. Roque F, Mon G, Belardi J, Rodriguez A, Grinfeld L, Long R, et al: Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA). Antisense Nucleic Acid Drug Dev 2001; 11: 99-106.

  5. Mannion JD, Ormont ML, Magno MG, O’Brien JE, Shi Y, Zalewski A: Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann Thorac Surg 1998; 66: 1948-1952.

  6. von Der Leyen HE, Dzau VJ: Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 2001; 103: 2760-2765.

  7. Freedman SB, Isner JM: Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001; 33: 379-393.

  8. Baumgartner I, Isner JM: Somatic gene therapy in the cardiovascular system. Annu Rev Physiol 2001; 63: 427-450.

  9. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309.

  10. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al: Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995; 91: 2687-2692.




2020     |     www.medigraphic.com